BioNTech CEO Sierk Pötting expects to be able to present the first data from the ongoing study on the efficacy of BNT162 at the end of...
Pfizer has stopped its research on the possible cure for Parkinson's and Alzheimer's diseases.
Centrexion Therapeutics will allot the funding to the next phase of its CNTX-4975 drug.
Spark is getting positive results with SPK-9001, an alternative drug for the treatment of a hereditary blood disorder.
With stiff competition from established medical companies and the stigma linked to marijuana, the challenges are real.